Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Personal Care R&D In Brief

This article was originally published in The Tan Sheet

Executive Summary

Probio mouthrinse for sale, license: Positive clinical trial results for Oragenics' Probiora3 probiotic mouthrinse position the firm to sell or license its technology, allowing it to focus on other R&D opportunities, specifically its MU1140 antibiotic candidate currently under development, the firm states Nov. 15. Probiora3 effectively reduces levels of disease-causing oral bacteria in young, healthy adult subjects, showing reductions in Streptococcus mutans, a teeth-decaying bacterium, and two bacterial strains linked to gum diseases in subjects using the product for one week, the Alachua, Fla.-based company says. "The oral probiotic represents a breakthrough approach to maintaining oral health by utilizing cultures of bacteria commonly found in healthy mouths to provide a natural defense against those bacteria thought to be harmful to teeth and gums," according to Oragenics' Scientific Advisory Committee Chairman Raman Bedi, DDS...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS099970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel